Related Experiment Videos
[Can superparamagnetic contrast media improve MRI-tomographic images of experimental gliomas?]
T Egelhof1, N Delbeck, M Hartmann
1Abteilung Neuroradiologie, Universität Heidelberg.
Purpose:
To investigate whether the margins of microscopic tumors can be delineated better with monocrystalline iron oxide nanoparticles (MION), a superparamagnetic contrast medium, than with Gd-DTPA by magnetic resonance imaging (MRI).
Methods:
MRI and histological examinations were conducted in 28 Wistar rats with sterotactically implanted gliomas (C6 gliomas). Of the 28 animals, 14 were examined after intravenous administration of MION [nine animals received 179 mmol Fe/kg body weight (dose 1), and five, 893 mmol Fe/kg (dose 2)]. The other 14 animals were examined first after i.v. administration of Gd-DTPA (0.2 mmol/kg) and then after i.v. administration of MION. The extent of the tumors as seen on MRI and at histological study were compared.
Results:
Iron particles were identified microscopically in tumor cells and in the tumoral interstitium. After administration of MION at dose 1, the contrast-enhanced area of tumor was 1.55-fold greater than the extent of tumor identified by histological study, at dose 2,2.15-fold. Compared with Gd-DTPA the area of contrast enhancement was greater by a factor of 1.38 with MION administration at dose 1 and by a factor of 1.91 at dose 2.
Conclusion:
MION provides intra- and extracellular contrast enhancement. The area of the contrast-enhanced tumor is dose-dependently greater with MION than with Gd-DTPA and also greater than the extent of tumor seen at histological study.
Insights
Monocrystalline iron oxide nanoparticles (MION) improve tumor margin delineation on MRI scans compared to Gd-DTPA. MION offers dose-dependent, enhanced contrast for better visualization of microscopic tumor extent.
Area of Science:
- Biomedical Imaging
- Nanotechnology
- Oncology
Background:
- Accurate delineation of microscopic tumor margins is crucial for effective cancer treatment.
- Superparamagnetic contrast agents are vital for enhancing MRI contrast.
- Monocrystalline iron oxide nanoparticles (MION) offer potential advantages over traditional contrast agents.
Purpose of the Study:
- To compare the efficacy of MION with Gd-DTPA in delineating microscopic tumor margins using MRI.
- To evaluate the dose-dependent effect of MION on tumor contrast enhancement.
Main Methods:
- MRI and histological examinations were performed on Wistar rats with implanted gliomas.
- Animals received intravenous administration of MION at two different doses or Gd-DTPA.
- Tumor extent on MRI was compared with histological findings.
Main Results:
- MION demonstrated intra- and extracellular contrast enhancement within tumor cells and interstitium.
- The contrast-enhanced tumor area was significantly larger with MION compared to Gd-DTPA.
- MION showed a dose-dependent increase in contrast enhancement, exceeding histological tumor extent.
Conclusions:
- MION provides superior contrast enhancement for tumor delineation compared to Gd-DTPA.
- The enhanced visualization of tumor margins with MION can aid in surgical planning and treatment efficacy.
- MION represents a promising contrast agent for improved MRI-based tumor detection.